Shanghai, China, May 14, 2025 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that it has been included in the MSCI Global Small Cap Indexes following the results of the MSCI Equity Indexes May 2025 Index Review. The inclusion will be implemented as of the close of May 30, 2025.
The MSCI Global Small Cap Indexes are among the most important global benchmarks compiled by MSCI, a leading international index provider. Widely used by institutional investors around the world for portfolio construction and performance measurement, these indexes represent a key indicator of market recognition. Henlius’ inclusion in the index marks a further elevation of the company’s visibility and influence in global capital markets and reflects strong recognition of its overall strength, R&D achievements, and global growth potential by the international investment community.
As an innovation-driven biopharmaceutical company listed on the Main Board of the Hong Kong Stock Exchange, Henlius achieved full-year profitability for the first time in 2023, driven by commercial sales of its core products, and sustained profitability throughout 2024, demonstrating solid business foundation and long-term growth prospects. Since its inception in 2010, the company has been committed to its patient-centric mission, building an integrated biopharmaceutical platform and accelerating the development of high-quality, accessible biologics through in-house innovation and global collaboration.
With a robust pipeline covering multiple therapeutic areas, Henlius has continue to expand its footprint, serving as a forerunner in the global expansion of China’s biopharmaceutical industry. To date, six products have been approved in China and four internationally, reaching over 50 countries and regions and benefiting more than 800,000 patients worldwide. Being included in the MSCI Global Small Cap Index is expected to attract increased attention from global investors and inject fresh momentum into the company’s continued advancement of its innovation and globalization strategy.
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “Being included in the MSCI Global Small Cap Indexes is a strong endorsement of our long-term strategic execution and sustained innovation capabilities. Staying true to our patient-centric principal, we will continue to accelerate our global footprint, enhance our corporate value, and deliver long-term returns for our shareholders—while enabling more patients to access high-quality biologic therapies.”
